It has been a whirlwind two weeks since our team attended the highly anticipated ESHRE 39th Annual Meeting in Copenhagen, and we are still buzzing with excitement. The response to our Felix™ device has been absolutely phenomenal, leaving us in awe of the interest it generated. We are thrilled to share that we are currently in negotiations with not one, but three global distributors. Brace yourselves for some major announcements in the near future!

The Felix™ device is an automated and operator independent system that has created much interest amongst reproduction and fertility professionals . By employing a proprietary process that combines electrophoresis and size exclusion membranes, the Felix™ device effectively separates sperm from raw semen while excluding cellular contaminants such as leukocytes and precursor germ cells.

This technology consists of two key components: a console that provides electrical power, and a sterile single use cartridge that effectively separates sperm from a semen sample in just six minutes.

As the first commercial product for Memphasys Ltd, the Felix™ device is creating great interest in international markets. We continue to invest in the required clinical studies and regulatory processes on a market by market basis.

But that’s not all!

We were pleasantly surprised by the immense scientific and commercial interest surrounding our formative oxidative stress assay . Oxidative stress, which often escalates with age, can have serious implications on overall health, including fertility in both humans and animals. Currently, the clinical assessment of oxidative stress is complex and labour-intensive. However, Memphasys is changing the game by developing a point-of-care diagnostic device that measures oxidative stress.

This groundbreaking technology utilises a biochemistry-based assay and is being specifically designed for bodily fluids such as semen, blood, and follicular fluid, with application in IVF clinics and physician rooms. Once successfully optimised and validated, the prototype device will undergo rigorous field testing to demonstrate its efficacy and explore exciting market opportunities.

We are incredibly proud of the progress we’ve made in advancing reproductive biotechnology and diagnostics. As we continue to innovate and redefine industry standards, stay tuned for more updates on our Felix™ device and our oxidative stress diagnostic device.

The future is filled with limitless possibilities, and Memphasys is leading the way!